<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84076">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02038049</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736X2202</org_study_id>
    <nct_id>NCT02038049</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
  <official_title>A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if a monoclonal antibody VAY736 can reduce disease
      activity in relapsing-remitting multiple sclerosis (RRMS) as compared to placebo. The study
      will also provide the first safety and tolerability information for VAY736 in RRMS patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cumulative number of new Gd-enhancing lesions</measure>
    <time_frame>8, 12, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective is to evaluate the effect of VAY736 on the cumulative number of new Gd-enhancing brain lesions in RRMS patient population at weeks 8, 12 and 16.
It will be analyzed by means of a negative binomial regression model (with factor &quot;treatment&quot;) adjusting for baseline lesion count and number of MRI scans.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new and cumulative number of new T1-weighted Gd-enhancing lesions at weeks 4, 8, 12 and 16</measure>
    <time_frame>4, 8, 12, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be compared separately at each week between treatment groups using a negative binomial regression model adjusting for baseline lesion count and number of MRI scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of all T1-weighted Gd-enhancing lesions at weeks 4, 8, 12 and 16</measure>
    <time_frame>4, 8, 12, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be compared separately at each week between treatment groups using a negative binomial regression model adjusting for baseline lesion count and number of MRI scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of new or enlarging T2-weighted Gd-enhancing lesions at weeks 4, 8, 12 and 16</measure>
    <time_frame>4, 8, 12, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be compared between treatment groups using a negative binomial regression model adjusting for baseline lesion count and number of MRI scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 burden of disease (total volume of T2-weighted lesions) at weeks 4, 8, 12 and 16.</measure>
    <time_frame>4, 8, 12, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline will be analyzed by ANCOVA separately at each week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects without any new MRI disease activity at weeks 4, 8, 12 and 16.</measure>
    <time_frame>4, 8, 12, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>At each week, the proportion between treatment groups will be compared using a logistic regression model adjusting for baseline lesion count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of confirmed relapses at week 16.</measure>
    <time_frame>16 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be compared using a negative binomial regression adjusting for baseline number of relapses in previous 2 years and log (time on study in years) as the offset variable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of relapse-free patients over the 16 weeks of the treatment period.</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be compared between treatment groups using a logistic regression model adjusting for baseline number of relapses in previous 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Estimated mean 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events and death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Relapse Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>VAY736</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of VAY736</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to VAY736</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo (infusion bag) administered intravenously. Placebo randomized patients will be offered optional VAY736 administration after week 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAY736</intervention_name>
    <arm_group_label>VAY736</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to VAY736</description>
    <arm_group_label>Placebo to VAY736</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        18 Years to 55 Years Male and Female

          -  Diagnosis of MS as defined by the 2010 revised McDonald criteria (Polman, et.
             al2011).

               -  A relapsing-remitting course of disease with:

               -  at least 1 documented relapse during the previous 12 months (but not within 30
                  days prior to randomization), or

               -  a positive Gd-enhancing lesion on brain MRI scan at screening.

               -  An Expanded Disability Status Scale (EDSS) score of 0-5.0 inclusive at
                  screening.

               -  No evidence of a relapse within 30 days prior to randomization.

        Exclusion Criteria:

          -  • A manifestation of another type of MS other than RRMS.

               -  Findings on screening or baseline brain MRI inconsistent with the diagnosis of
                  MS.

               -  History of chronic disease of the immune system other than MS, or a known
                  immunodeficiency syndrome

               -  Women of child-bearing potential, defined as all women physiologically capable
                  of becoming pregnant, unless they are using highly effective methods of
                  contraception during dosing and for 4 months following completion of the study.

               -  Unable to undergo MRI scans due to inter-alia, claustrophobia, incompatible
                  cardiac pacemakers, ferromagnetic intracranial aneurysm clips,  certain cochlear
                   implants, and certain other ferromagnetic foreign bodies (e.g. tattoos
                  containing metal) or electronic devices, or metallic implants incompatible with
                  MRI.

               -  Unable to receive gadolinium-based MRI contrast agents due to a history of
                  hypersensitivity to gadolinium-based contrast agents, renal insufficiency or
                  impairment.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>501 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <state>Russia</state>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sestroreck</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tver</city>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Odesa</city>
        <zip>65117</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaporozhye</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Magnetic Resonance Imaging, VAY736, monoclonal antibody, gadolinium [Gd]-enhancing lesions, B-Cell</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
